CDK Global (CDK) Tops Q4 EPS by 3c

CDK Global (NASDAQ: CDK) reported Q4 EPS of $0.49, $0.03 better than the analyst estimate of $0.46. Revenue for the quarter came in at $542.2 million versus the consensus estimate of $533.84 million.

Fiscal 2017 guidance, fiscal 2018 and 2019 targets

• Fiscal 2017 GAAP net earnings attributable to CDK margin expansion of 200-250 bps and adjusted EBITDA margin expansion of 500-550 bps
• Fiscal 2017 GAAP net earnings attributable to CDK exit margin of approximately 13% and adjusted EBITDA exit margin of approximately 33%
• Fiscal 2018 targets of revenue growth of approximately 5% from fiscal 2017, adjusted EBITDA dollar growth of 44-48% from fiscal 2016, adjusted EBITDA margin of 35% and adjusted EBITDA exit margin of 36-38%
• Fiscal 2019 target of adjusted EBITDA exit margin of 40% or above

For earnings history and earnings-related data on CDK Global (CDK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c